JP6624787B2 - 脳内出血を治療するための組成物および方法 - Google Patents

脳内出血を治療するための組成物および方法 Download PDF

Info

Publication number
JP6624787B2
JP6624787B2 JP2015011332A JP2015011332A JP6624787B2 JP 6624787 B2 JP6624787 B2 JP 6624787B2 JP 2015011332 A JP2015011332 A JP 2015011332A JP 2015011332 A JP2015011332 A JP 2015011332A JP 6624787 B2 JP6624787 B2 JP 6624787B2
Authority
JP
Japan
Prior art keywords
ich
fxa
hours
pharmaceutical composition
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015011332A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015147764A5 (OSRAM
JP2015147764A (ja
Inventor
アーキン スティーヴン
アーキン スティーヴン
フルービス ジョアキム
フルービス ジョアキム
イー． カー マーカス
イー． カー マーカス
ヘット スニタ
ヘット スニタ
ジャスジャ リーマ
ジャスジャ リーマ
ディ． ピットマン デブラ
ディ． ピットマン デブラ
Original Assignee
ファイザー・インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイザー・インク filed Critical ファイザー・インク
Publication of JP2015147764A publication Critical patent/JP2015147764A/ja
Publication of JP2015147764A5 publication Critical patent/JP2015147764A5/ja
Application granted granted Critical
Publication of JP6624787B2 publication Critical patent/JP6624787B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2015011332A 2014-01-24 2015-01-23 脳内出血を治療するための組成物および方法 Expired - Fee Related JP6624787B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461931071P 2014-01-24 2014-01-24
US61/931,071 2014-01-24

Publications (3)

Publication Number Publication Date
JP2015147764A JP2015147764A (ja) 2015-08-20
JP2015147764A5 JP2015147764A5 (OSRAM) 2018-03-01
JP6624787B2 true JP6624787B2 (ja) 2019-12-25

Family

ID=52630418

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015011332A Expired - Fee Related JP6624787B2 (ja) 2014-01-24 2015-01-23 脳内出血を治療するための組成物および方法

Country Status (18)

Country Link
US (2) US20160375109A1 (OSRAM)
EP (1) EP3096779B1 (OSRAM)
JP (1) JP6624787B2 (OSRAM)
KR (3) KR20160093731A (OSRAM)
CN (2) CN105934250A (OSRAM)
AU (1) AU2015208819B2 (OSRAM)
BR (1) BR112016014617A2 (OSRAM)
CA (1) CA2937418A1 (OSRAM)
DK (1) DK3096779T3 (OSRAM)
ES (1) ES2772802T3 (OSRAM)
HU (1) HUE047588T4 (OSRAM)
IL (1) IL246637A0 (OSRAM)
MX (1) MX375355B (OSRAM)
PL (1) PL3096779T3 (OSRAM)
PT (1) PT3096779T (OSRAM)
RU (1) RU2016126423A (OSRAM)
SI (1) SI3096779T1 (OSRAM)
WO (1) WO2015110939A1 (OSRAM)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150103205A (ko) 2013-01-31 2015-09-09 화이자 인코포레이티드 인자 Xa 억제를 길항하기 위한 조성물 및 방법
SG11201601221XA (en) 2013-09-24 2016-04-28 Pfizer Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2570330A1 (en) * 2004-06-21 2005-12-29 Novo Nordisk Health Care A/S Use of factor viia or factor viia equivalents for preventing or attenuating haemorrhage growth, and/or oedema generation following intracerebral haemorrhage (ich)
MX336958B (es) * 2005-11-15 2016-02-05 Philadelphia Children Hospital Metodos y composiciones para modular la hemostasia.
CN101918025A (zh) * 2008-01-18 2010-12-15 诺沃-诺迪斯克保健股份有限公司 因子Ⅶa或因子Ⅶa等同物用于防止或减弱选择的脑内出血患者亚群在脑内出血(ICH)后出血增多和/或水肿形成的用途
JP6163304B2 (ja) * 2009-07-15 2017-07-12 ポートラ ファーマシューティカルズ， インコーポレイテッド 第Ｘａ因子インヒビターの解毒剤の単位用量処方物およびその使用方法
WO2011020866A2 (en) * 2009-08-20 2011-02-24 Csl Behring Gmbh Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
US9371522B2 (en) * 2011-09-30 2016-06-21 The Children's Hospital Of Philadelphia Compositions and methods for modulating hemostasis
SG11201500579SA (en) * 2012-07-25 2015-02-27 Catalyst Biosciences Inc Modified factor x polypeptides and uses thereof
KR20150103205A (ko) * 2013-01-31 2015-09-09 화이자 인코포레이티드 인자 Xa 억제를 길항하기 위한 조성물 및 방법

Also Published As

Publication number Publication date
PT3096779T (pt) 2020-02-21
CN105934250A (zh) 2016-09-07
IL246637A0 (en) 2016-08-31
ES2772802T3 (es) 2020-07-08
SI3096779T1 (sl) 2020-03-31
RU2016126423A (ru) 2018-03-01
KR20210008177A (ko) 2021-01-20
PL3096779T3 (pl) 2020-05-18
EP3096779B1 (en) 2019-12-18
DK3096779T3 (da) 2020-02-24
CN112156176A (zh) 2021-01-01
RU2016126423A3 (OSRAM) 2018-03-01
US20190231856A1 (en) 2019-08-01
CA2937418A1 (en) 2015-07-30
BR112016014617A2 (pt) 2017-09-19
US20160375109A1 (en) 2016-12-29
WO2015110939A1 (en) 2015-07-30
KR20180014221A (ko) 2018-02-07
MX2016009665A (es) 2016-11-14
KR20160093731A (ko) 2016-08-08
AU2015208819A1 (en) 2016-06-30
EP3096779A1 (en) 2016-11-30
HUE047588T4 (hu) 2020-06-29
JP2015147764A (ja) 2015-08-20
HUE047588T2 (hu) 2020-04-28
AU2015208819B2 (en) 2020-01-23
MX375355B (es) 2025-03-04

Similar Documents

Publication Publication Date Title
JP5785687B2 (ja) 急性虚血性脳卒中を処置するためのテネクテプラーゼの使用
US20220298261A1 (en) Serpinf2-Binding Molecules and Method of Use Thereof
JP2016511755A (ja) 第Ｘａ因子の阻害を中和するための組成物および方法
KR20160016756A (ko) Adamts13의 피하 투여
JP2004508280A (ja) 活性化プロテインｃ（ａｐｃ）の神経保護薬、抗血栓薬および抗炎症薬としての使用
JP2017502036A (ja) 血友病の予防的処置のための第ｉｘ因子を含む融合タンパク質およびその方法
JP2012197279A (ja) 脳内出血（ＩＣＨ）に続く出血の増大、および／または浮腫の発生の予防および減弱化のための、第ＶＩＩａ因子または第ＶＩＩａ因子均等物の使用
US20190231856A1 (en) Compositions and methods for treating intracerebral hemorrhage
JP2022519327A (ja) 頭蓋内出血の治療方法及び効果の評価方法
HK40040435A (en) Compositions and methods for treating intracerebral hemorrhage
EP3420087B1 (en) Peptide-based methods for treating neurological injury
JP6629744B2 (ja) 第Ｘａ因子の半減期を延ばす組成物および方法
HK1228257A1 (en) Compositions and methods for treating intracerebral hemorrhage
JP2009501188A (ja) 抗血小板療法で治療される患者における脳内出血（ＩＣＨ）後の出血増大及び／又は浮腫形成を予防又は軽減するための第ＶＩＩａ因子又は第ＶＩＩａ因子等価物の使用
JP7515557B2 (ja) 凝固異常を伴う敗血症の治療及び／又は改善のための医薬
US20230285523A1 (en) Use of elafin in the treatment of covid-19
US20170042981A1 (en) Half-life extended factor fviia protein for prevention and treatment of bleeding and dosing regimens therefor
AU2018294517B2 (en) 21-day dosing regimen for fusion proteins comprising factor IX and human albumin for prophylactic treatment of hemophilia and methods thereof
WO2026076443A1 (en) Methods for treating factor x deficiency

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180116

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190403

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190729

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191008

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20191112

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191126

R150 Certificate of patent or registration of utility model

Ref document number: 6624787

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees